Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2022

View Archived Issues

S100A4 levels correlate with active eosinophilic esophagitis

IL13RA1 is a therapeutic target in the treatment of EoE

New complement factor B inhibitors identified at Shanghai Meiyue Biotech Development

PROTACs targeting IRAK-4 synthesized at Shanghai Leadingtac Pharmaceutical

Kira Pharmaceuticals discovers C5aR antagonists

BeiGene divulges new G12C mutant GTPase KRAS inhibitors

Beijing Tide Pharmaceutical patents son of sevenless homolog 1 inhibitors

Fibulin-2 as a novel therapeutic target in multiple sclerosis

Study finds potential entry points to Huntington's therapy

Targeting MRGPRX2-mediated mast cell activation as a therapeutic strategy for atopic dermatitis

Discovery of novel orally bioavailable inhibitors of EGFR T790M/C797S mutants

ANGPTL4 is elevated in peanut allergy

Tonix enters research agreement with Inserm to study oxytocin in Prader-Willi syndrome mouse model

PBI-0451 shows promising results for the treatment of COVID-19

SpFN_1B-06-PL vaccine induces durable immune response against pathogens

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...